Ping Liu

US Patent:

6470057, Oct 22, 2002

Filed:

Oct 9, 1998

Appl. No.:

09/169273

Inventors:

Liu Hui - Issaquah WA
Guanghan Xu - Austin TX
Ping Liu - Austin TX

Assignee:

Cwill Telecommunications, Inc. - Richardson TX

International Classification:

H01L 514

US Classification:

375294, 370350, 370516, 375356, 375358

Abstract:

In a synchronous code division multiple access (SCDMA) time division duplex (TDD) communication system, a remote terminal uses both open loop and closed loop techniques for synchronization with a base station. The timing of reception of information by tile remote terminal is performed with an open loop technique, while the timing of transmissions from the terminal is performed with a closed loop technique. Furthermore, a clock locked loop in the terminal compensates for differences between clocks of the terminal and the base station. The clock locked loop responds to signals from both the aforesaid open loop and closed loop techniques.

US Patent:

6972295, Dec 6, 2005

Filed:

Mar 12, 2003

Appl. No.:

10/387265

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K031/4412
C07D213/70

US Classification:

514345, 546290

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7514409, Apr 7, 2009

Filed:

Mar 7, 2005

Appl. No.:

10/591820

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Richard A. Mumford - Red Bank NJ, US
Thomas S. Reger - San Diego CA, US
Nicholas D. Smith - San Diego CA, US
Nicholas S. Stock - San Diego CA, US
Jasmine Zunic - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 38/05

US Classification:

514 19

Abstract:

Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.

US Patent:

7550489, Jun 23, 2009

Filed:

Feb 1, 2008

Appl. No.:

12/012463

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/435

US Classification:

514354, 514355

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7816534, Oct 19, 2010

Filed:

Apr 16, 2009

Appl. No.:

12/386336

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/44
C07D 213/04
C07D 401/02
C07D 403/02
C07D 239/02

US Classification:

546255, 546266, 5462681, 544238, 514256, 514336, 514340

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

8153626, Apr 10, 2012

Filed:

Dec 7, 2007

Appl. No.:

12/517836

Inventors:

Robert K. Baker - Cranford NJ, US
Linda L. Chang - Wayne NJ, US
Marc Chioda - Metuchen NJ, US
Harry R. Chobanian - Aberdeen NJ, US
Yan Guo - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Kathleen M. Rupprecht - Cranford NJ, US
Shouwu Miao - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/62
A61K 31/55
C07D 491/00
C07D 513/00
C07D 515/00
C07D 243/10
C07D 487/12

US Classification:

514220, 540557

Abstract:

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

US Patent:

8455528, Jun 4, 2013

Filed:

Jun 4, 2009

Appl. No.:

12/996429

Inventors:

Linus S. Lin - Westfield NJ, US
Marc D. Chioda - Metuchen NJ, US
Ping Liu - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4174
A61K 31/4178
C07D 233/84

US Classification:

514397, 5483111

Abstract:

The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

US Patent:

20050234061, Oct 20, 2005

Filed:

Apr 19, 2005

Appl. No.:

11/109076

Inventors:

William Hagmann - Westfield NJ, US
Linus Lin - Westfield NJ, US
Shrenik Shah - Metuchen NJ, US
Ravindra Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen Armstrong - Westfield NJ, US
James Jewell - Jersey City NJ, US
Thomas Lanza - Edison NJ, US

International Classification:

A61K031/502
A61K031/428
A61K031/423
A61K031/4196
A61K031/405
A61K031/401
A61K031/165

US Classification:

514248000, 514367000, 514375000, 514423000, 514419000, 514617000, 514383000, 544237000, 548152000, 548217000, 548495000, 548537000

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.